Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization

Vaccine

Volumn 29, Issue 40, 2011, Pages 6994-7001

  Madhi, Shabir A ^a,b   Violari, Avy ^a   Klugman, Keith P ^a,c   Lin, Gina ^d   McIntyre, James A ^e   von Gottberg, Anne ^b   Jean Philippe, Patrick ^f   Cotton, Mark F ^g   Adrian, Peter ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Pharmaceutical Product Development   (United States)

^e ANOVA   (South Africa)

^f HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^g STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Colonization; HIV; Hypo responsiveness; Immunogenicity; Pneumococcal conjugate vaccine; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; CHILD; COMPARATIVE STUDY; FEMALE; GEOMETRIC MEAN ANTIBODY CONCENTRATION; GEOMETRIC MEAN TITER; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; NASOPHARYNGEAL COLONIZATION; OPSONOPHAGOCYTOSIS ACTIVITY ASSAY; PHAGOCYTOSIS; PRIORITY JOURNAL; QUALITATIVE ANTIBODY RESPONSE; QUANTITATIVE ANTIBODY RESPONSE; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ANTIBODIES, BACTERIAL; HIV INFECTIONS; HUMANS; IMMUNIZATION; INFANT; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 80052340389     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.035     Document Type: Article

References (28)

1. O'Brien K.L., Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 2003, 21(17-18 (May 16)):1815-1825.
2. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999, 180(4):1171-1176.
3. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19(3 (March)):187-195.
4. Nurkka A., Ahman H., Korkeila M., Jantti V., Kayhty H., Eskola J. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001, 20(1):25-33.
5. Obaro S.K., Adegbola R.A., Chang I., Banya W.A., Jaffar S., Mcadam K.W., et al. Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr Infect Dis J 2000, 19(5):463-469.
6. Salt P., Banner C., Oh S., Yu L.M., Lewis S., Pan D., et al. Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood. Clin Vaccine Immunol 2007, 14(5 (May)):593-599.
7. Rabquer B., Shriner A.K., Smithson S.L., Westerink M.A. B cell mediated priming following pneumococcal colonization. Vaccine 2007, 25(11 (March 1)):2036-2042.
8. Dagan R., Givon-Lavi N., Greenberg D., Fritzell B., Siegrist C.A. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010, 201(10 (May 15)):1570-1579.
9. Vakevainen M., Soininen A., Lucero M., Nohynek H., Auranen K., Makela P.H., et al. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J Pediatr 2010, 157(5 (November)). 778-83.e1.
10. Madhi S.A., Adrian P., Cotton M.F., McIntyre J.A., Jean-Philippe P., Meadows S., et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010, 202(3 (August 15)):355-361.
11. Violari A., Cotton M.F., Gibb D.M., Babiker A.G., Steyn J., Madhi S.A., et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008, 359(21 (November 20)):2233-2244.
12. O'Brien K.L., Bronsdon M.A., Dagan R., Yagupsky P., Janco J., Elliott J., et al. Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. J Clin Microbiol 2001, 39(3 (March)):1021-1024.
13. Jodar L., Butler J., Carlone G., Dagan R., Goldblatt D., Kayhty H., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003, 21(23 (July 4)):3265-3272.
14. Millar E.V., O'Brien K.L., Zell E.R., Bronsdon M.A., Reid R., Santosham M. Nasopharyngeal carriage of Streptococcus pneumoniae in Navajo and White Mountain Apache children before the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2009, 28(8 (August)):711-716.
15. O'Brien K.L., Moisi J., Moulton L.H., Madore D., Eick A., Reid R., et al. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. J Infect Dis 2007, 196(1 (July 1)):104-114.
16. Gill C.J., Mwanakasale V., Fox M.P., Chilengi R., Tembo M., Nsofwa M., et al. Impact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian women. J Infect Dis 2008, 197(7 (April 1)):1000-1005.
17. Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010, 28(25 (June 7)):4192-4203.
18. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365(9465 (April)):1139-1146.
19. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349(14 (October 2)):1341-1348.
20. O'Brien K.L., Moulton L.H., Reid R., Weatherholtz R., Oski J., Brown L., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003, 362(9381 (August 2)):355-361.
21. Siber G.R., Chang I., Baker S., Fernsten P., O'brien K.L., Santosham M., et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007, 25(19 (May 10)):3816-3826.
22. Huang S.S., Platt R., Rifas-Shiman S.L., Pelton S.I., Goldmann D., Finkelstein J.A. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005, 116(3 (September)):e408-e413.
23. O'Brien K.L., Millar E.V., Zell E.R., Bronsdon M., Weatherholtz R., Reid R., et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 2007, 196(8 (October 15)):1211-1220.
24. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(18 (May 1)):1737-1746.
25. Van Effelterre T., Moore M.R., Fierens F., Whitney C.G., White L., Pelton S.I., et al. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine 2010, 28(21 (May 7)):3650-3660.
26. Lacapa R., Bliss S.J., Larzelere-Hinton F., Eagle K.J., McGinty D.J., Parkinson A.J., et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis 2008, 47(4 (August 15)):476-484.
27. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007, 297(16 (April 25)):1784-1792.
28. Hill P.C., Townend J., Antonio M., Akisanya B., Ebruke C., Lahai G., et al. Transmission of Streptococcus pneumoniae in rural Gambian villages: a longitudinal study. Clin Infect Dis 2010, 50(11 (June 1)):1468-1476.